Quarter 3, March 2026 - May 2026
- Net revenue was 8 933 (6 686) tkr.
- EBITDA was -3 964 (-5 691) tkr.
- Operating cash flow was -10 286 (-5 787) tkr.
Interim period, September 2025 - May 2026
- Net revenue was 29 107 (25 658) tkr.
- EBITDA was -13 168 (-10 423) tkr.
- Operating cash flow was -14 575 (-7 366) tkr.
- Cash position in the end of period was 14 679 (11 672) tkr.
Significant events during the quarter
- Newbury Pharmaceuticals has entered into a partnership with a new partner to register and launch Prucalopride tablets in Sweden.
- Newbury Pharmaceuticals extends and increases loan agreement to 30 mkr, as resolved by the Extraordinary General Meeting held on 15 April.
- Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury
Significant events after the end of the quarter
- No significant events have occurred after the end of the quarter.
A word from the CEO
Turnover and Performance
During the third quarter of the 2025/2026 financial year (March 2026 - May 2026), Newbury Pharmaceuticals reported net revenue of SEK 8.9 million, up from SEK 6.7 million in the same quarter last year, an increase of approximately 34%. For the first nine months of the financial year, cumulative net revenue reached SEK 29.1 million, compared to SEK 25.7 million in the corresponding period last year, representing growth of approximately 13%.
Revenue in the period was generated primarily from the Nordic markets. Quarterly sales continue to reflect the inherent variability of tender-driven demand, which by nature fluctuates across quarters, and we expect annual sales to keep growing as the portfolio expands and more products reach the market.
EBITDA for the third quarter amounted to SEK -4.0 million, an improvement of SEK 1.7 million on the SEK -5.7 million reported a year earlier, while EBITDA for the first nine months was SEK -13.2 million (SEK -10.4 million). The operating result for the quarter was SEK -4.4 million (SEK -6.2 million). The higher cost base is driven mainly by cost of goods sold rising in line with growing sales volumes. Costs remain under control, and we stay focused on keeping cost development proportionate to revenue growth as we scale the business
Portfolio Development
The Company continued to build its product portfolio across the Nordic markets, and we now have 24 products launched in the Nordics. Our target of reaching more than 30 launched products by the end of 2026 remains in place, subject to the timing of regulatory approvals and market access processes.
During the quarter we secured generic approval for Palbociclib Newbury, further strengthening our specialty and oncology offering.
Since the beginning of the financial year, Newbury has been assigned as local distributor for five new distributor products; Posaconazole, Brivaracetam, Atomoxetin, Anastrozole and Irinotecan. We intend to launch most of these new products during 2026 or as soon as regulatory exclusivities and patents allow us. The distributor portfolio will continue to grow with more products being registered in the Nordics which shows the strength of this strategic partnership.
A broader launched portfolio strengthens our ability to participate in tenders across multiple therapeutic areas, which over time should support a more stable and diversified sales base. We have also built inventory ahead of the second half of the year in anticipation of planned launches and tender activity.
Financial Position
Cash and bank balances at 31 May 2026 were SEK 14.7 million, broadly stable versus SEK 14.6 million at the start of the financial year, supported by the financing secured during the quarter. Equity stood at SEK 26.3 million, giving a solidity ratio of approximately 31%, with the reduction over the year reflecting the result during our current investment and scale-up phase. Total assets amounted to SEK 84.5 million, and the intangible asset base of SEK 29.7 million reflects the product registrations and intellectual property underpinning our commercial activities.
In the quarter we agreed to extend and increase the existing loan facility with AB Slädens Pensionsstiftelse nr 3 to a total of SEK 30 million, with maturity extended to 30 June 2027. Given the related-party nature of the transaction, the amendment was approved at the Extraordinary General Meeting held on 15 April 2026. This financing strengthens our platform and gives us the runway to continue executing our growth strategy.
Outlook
My primary focus as CEO remains reaching EBITDA breakeven as the foundation for long-term, profitable growth, and every decision we make - on portfolio prioritization, cost management and commercial execution - is guided by that goal. We expect the final quarter of the financial year to benefit from additional product launches and a growing number of products active in tenders across the Nordics. As the portfolio expands, improving gross margins should increasingly offset the fixed cost base, and the SEK 30 million facility secured through June 2027 gives us the platform to deliver on this strategy.
I would like to thank our shareholders, partners and employees for their continued support, and I look forward to reporting on further progress.
The report is publised on Newbury Pharmaceuticals website:
https://www.newburypharma.com/investors/financial-information/
For more information, contact:
Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20
www.newburypharma.com
About Newbury Pharmaceuticals
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.
Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.
This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-08 08:00 CEST.
